Journal profile · ONCOLOGY
Current Problems in Cancer: Case Reports
ISSN 2666-6219 · Elsevier
Current Problems in Cancer: Case Reports: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 0.5 (journal website); fully open access; APC about USD 1,210; review about 149 days (submission to acceptance, publisher); 55 articles in 2025; indexed in ESCI and Scopus.
Scope
Aims, scope and focus
Current Problems in Cancer: Case Reports is published by Elsevier and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Cancer Immunotherapy and Biomarkers, Lung Cancer Treatments and Mutations and Cancer and Skin Lesions, together about 22.8% of its articles. Its main subfields are Oncology. (generated from OpenAlex topic counts and CAS ranking data)
Current Problems in Cancer: Case Reports is an international, peer-reviewed open access Journal publishing oncology case reports. It aims to share awareness of groundbreaking cases that give insight into redefining concepts in cancer. Our topics are comprehensive, encompassing new understandings of cancer diagnosis, tumor biology, and treatment decisions. We also welcome tumor board reports which showcase multidisciplinary discussions of illustrative cases within a defined tumor group.A companion title to Current Problems in Cancer, the Journal provides a global forum for clinicians and researchers to share their personal experiences through case reports. We hope that academic and community physicians, providers, and students will participate and learn from this collection of case reports.
From the journal's Aims & Scope
Research area (LetPub): ONCOLOGY
Editorial board by country: 6 in mainland China (about 3%); most named United States 70, Italy 32, India 23, Japan 13, Spain 10 (240 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Cancer Immunotherapy and BiomarkersMedicine8.4%
- Lung Cancer Treatments and MutationsMedicine8.4%
- Cancer and Skin LesionsMedicine5.9%
- Neuroendocrine Tumor Research AdvancesMedicine5.8%
- Chronic Lymphocytic Leukemia ResearchMedicine5.4%
- Cancer Diagnosis and TreatmentMedicine5.4%
- Sarcoma Diagnosis and TreatmentMedicine4.8%
- Lung Cancer Research StudiesMedicine4.8%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Not covered
Not covered by this edition.
Database indexing
ESCIScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor (publisher)
- 0.5Publisher website ·
- CiteScore 2026-06
- 0.6LetPub ·
- CiteScore (publisher)
- 0.6Publisher website ·
- SJR 2026-06
- 0.19LetPub ·
- SNIP 2026-06
- 0.18LetPub ·
- h-index
- 8OpenAlex ·
- i10-index
- 6OpenAlex ·
- 2-year mean citedness
- 0.34OpenAlex ·
- Self-citation rate
- 20%LetPub ·
- Share of gold OA articles
- 100%LetPub ·
Volume
- Articles per year
- 47LetPub ·
Articles by year OpenAlex count · 434 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 45 | 45 | 2 |
| 2025 | 55 | 55 | 7 |
| 2024 | 66 | 66 | 48 |
| 2023 | 57 | 57 | 50 |
| 2022 | 79 | 79 | 76 |
| 2021 | 82 | 82 | 142 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Publisher-reported review time from the journal's website
149 dayssubmission to acceptance · community reports about 8 weeks
The publisher's own definition applies; dates from this journal's articles in the last 24 months are not available yet, so the publisher's figure is used.
Figures by source
- Average review time (community reports)
- about 8 weeksLetPub ·
- Submission to first decision
- 9 daysPublisher website ·
- First decision after review
- 81 daysPublisher website ·
- Submission to acceptance
- 149 daysPublisher website ·
- Acceptance to publication
- 4 daysPublisher website ·
- Submission to publication (journal-reported)
- about 22 weeksDOAJ ·
- Peer review
- Single anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | USD 1,210 | Yes | CC BY, CC BY-NC, CC BY-NC-ND | |
| OpenAlex | USD 1,030 / EUR 960 / GBP 820 / JPY 127,750 | — | — | |
| LetPub | USD 650 | Yes | — | |
| Publisher website | USD 1,510 | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare2 items from the author guidelines
- Abstract
- ≤ 250 words
- Keywords
- 1–7
Policy excerpts from the journal's websiteAI use, Authorship, Conflicts of interest, License & copyright, Open access, Peer review, Preprints
- AI use Declaration of generative AI use
Authors must declare the use of generative AI tools in the manuscript preparation process upon submission of the paper.Generative AI and AI-assisted technologies (“AI tools”) have been rapidly adopted in research and scholarly publishing, offering significant benefits while requiring clear standards for responsible and transparent use.Authors preparing a manuscript for this journal may use AI tool…
Source ↗Publisher website ·- Authorship Group authorship
Group authorship refers to the attribution of an article to a defined and named group of authors whose members have contributed to the work. Examples include research consortia, clinical trial groups, collaborative networks, task forces or working groups, expert panels or consensus groups, and participatory research groups. Group authorship must be declared on the title page at submission. When av…
Source ↗Publisher website ·- Conflicts of interest Declaration of competing interests
All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence or bias their work. Examples of potential competing interests include:EmploymentConsultanciesStock ownershipHonorariaPaid expert testimonyPatent applications or registrationsGrants or any other fundingAffiliation with the journal as an Editor or Advisory Board …
Source ↗Publisher website ·- License & copyright License options
Authors will be offered open access user license options which will determine how you, and third parties, can reuse your open access article. We advise that you review these options and any funding body license requirements before selecting a license option.
Source ↗Publisher website ·- Open access Open access
We refer you to our open access information page to learn about open access options for this journal.
Source ↗Publisher website ·- Peer review Peer review
Single anonymized review process Model summary
This journal follows a single anonymized review process. Your submission will initially be assessed by our editors. If your submission is deemed suitable, it will typically be sent to be reviewed by a minimum of two reviewers for an independent expert assessment of the scientific quality. The decision as to whether your article is accepted or rejected for publication will be made by our editors.Re…
Source ↗Publisher website ·- Preprints Preprints
Preprint sharingAuthors may share preprints in line with Elsevier's article sharing policy. Sharing preprints, such as on a preprint server, will not count as prior publication.We advise you to read our policy on multiple, redundant or concurrent publication. In support of Open Science, this journal offers its authors a free preprint posting service on SSRN, Elsevier’s preprint and early research …
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Elsevier
- ISSN
- 2666-6219
- Official links
- Journal homepage ↗DOAJ
- Submission system ↗Publisher website
- Author guidelines ↗DOAJ
- Aims & Scope ↗DOAJ
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗DOAJ
- Editorial board ↗DOAJ
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about Current Problems in Cancer: Case Reports
What CAS zone is Current Problems in Cancer: Case Reports in?
In the 2025 upgraded edition of the CAS Journal Ranking, Current Problems in Cancer: Case Reports is in Zone 4 of Medicine, and in Zone 4 of the minor category Oncology. In the 2026 Xinrui edition it is in Zone 4 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Current Problems in Cancer: Case Reports?
The journal's website gives an impact factor of 0.5; this is the journal's own figure, as LetPub lists none for it; CiteScore 0.6, h-index 8.
How long does peer review take at Current Problems in Cancer: Case Reports?
The publisher reports about 149 days (submission to acceptance); authors report an average review time of about 8 weeks. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of Current Problems in Cancer: Case Reports?
According to the journal's author guidelines: Abstract: ≤ 250 words; Keywords: 1–7. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of Current Problems in Cancer: Case Reports based?
Of the 240 board members whose country the journal's board page names, 6 (about 3%) are in mainland China; the countries named most often are United States (70), Italy (32) and India (23). Counted from the institutions listed on the board page; for reference only.
Which databases index Current Problems in Cancer: Case Reports?
According to LetPub and DOAJ records, Current Problems in Cancer: Case Reports is indexed in ESCI, Scopus and DOAJ.
Is Current Problems in Cancer: Case Reports open access, and what is the APC?
Current Problems in Cancer: Case Reports is a fully open-access journal. APC about USD 1,210.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex, DOAJ; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .